Vertex Pharmaceuticals IncorporatedVRTX

Healthcare
Bullish

ASignal's systematic analysis rates VRTX as Bullish. Vertex Pharmaceuticals Incorporated has a market cap of $121.09B, a P/E of 28.33, a 35.5% net margin, and 7.8% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Aug 1, 2026

The case on VRTX

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Strong free cash flow of $2.78B
  • High return on equity at 24.20%
  • Low debt-to-equity ratio of 0.10x
  • Operating margin of 38.13% indicates pricing power
  • Forward P/E of 22.36x below current P/E, suggesting earnings growth expectations
VS
Bear case
  • MACD below signal line with negative histogram, indicating weakening momentum
  • Price below both SMA20 and SMA50, suggesting short-term downtrend
  • RSI near neutral at 47.43, lacking strong bullish momentum
  • No Reddit mentions, indicating low retail investor interest

Key facts

Sector
Healthcare
Market cap
$121.09B
P/E ratio
28.33
Gross margin
54.4%
Net margin
35.5%
Rev growth YoY
7.8%
Price (Aug 1, 2026)
$477.1

Peers

Clustered with VRTX by analysis-profile similarity.

Subscriber-only

See the full verdict on VRTX

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes VRTX

Most investors never get a second opinion, let alone several. ASignal runs VRTX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis - ASignal rates it Bullish